Greece vs Micronesia (country): Statin use vs. average non-HDL cholesterol levels
Greece
3.5
in 2018
Micronesia (country)
3.5
in 2018
Greece rank
52nd
Micronesia (country) rank
52nd
Statin use vs. average non-HDL cholesterol levels over time
- Greece
- Micronesia (country)
How they compare
Greece currently reports 3.5 against 3.5 in Micronesia (country), a difference of 0.
The two have swapped places 5 times across 39 shared years of data; in 1980 it was Greece ahead.
Greece ranks 52nd and Micronesia (country) ranks 52nd of 191 countries.
Greece has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Greece | Micronesia (country) | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 4.18 | 3.52 | 0.66 | Greece |
| 1990s | 3.85 | 3.68 | 0.17 | Greece |
| 2000s | 3.61 | 3.56 | 0.05 | Greece |
| 2010s | 3.5 | 3.5 | 0 | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher statin use vs. average non-hdl cholesterol levels, Greece or Micronesia (country)?
- Greece, at 3.5 against 3.5 in Micronesia (country) as of 2018.
- What is the difference in statin use vs. average non-hdl cholesterol levels between Greece and Micronesia (country)?
- 0, with Greece ahead.
- How many years of comparable data are there for Greece and Micronesia (country)?
- 39 years are reported by both, from 1980 to 2018.
- How do Greece and Micronesia (country) rank globally for statin use vs. average non-hdl cholesterol levels?
- Greece ranks 52nd and Micronesia (country) ranks 52nd of 191 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.